News

Immunoprecise to Strategically Invest in Foundational Next Generation Antibody Discovery Technology

Victoria, British Columbia, Canada, January 22, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a letter of intent with Single Cell Technology, Inc. (“Single Cell”) whereby the Company has agreed to strategically invest $5M (USD) in the expansion and development of production capability for Single Cell’s … Continue reading

ImmunoPrecise to Acquire Crossbeta Research BV

Victoria, British Columbia, Canada, December 22, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with Crossbeta Biosciences B.V. (“Crossbeta“) whereby the Company has agreed to acquire all of the issued and outstanding shares of Crossbeta (the “Transaction”). The Transaction continues to … Continue reading

ImmunoPrecise to Acquire ModiQuest Research BV

VICTORIA, Dec. 7, 2017 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with ModiQuest Research BV (“ModiQuest“) whereby the Company has agreed to acquire all of the issued and outstanding shares of ModiQuest (the “Transaction“). The Transaction continues to realize on the Board’s commitment … Continue reading

TetraGenetics and ModiQuest Collaborating for the Discovery of Therapeutic Antibodies against KCa3.1

Arlington, MA December 6, 2017 –– TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases, today announced a collaboration with ModiQuest Research, a Dutch biotechnology company with a suite of technologies for the discovery and optimization of monoclonal antibodies, including those directed against difficult target antigens with low immunogenicity. The alliance is focused on … Continue reading

Antibody Engineering and Therapeutics conference, San Diego, Dec 11 – 15 (booth#321)

ModiQuest Research, a leading custom antibody generation and development company, will be attending the Antibody Engineering and Therapeutics conference from December 11 till December 15 in San Diego. Immunized animals are still a key source of antibodies generated within therapeutic campaigns to obtain high affinity antibody drug candidates. Therefore, humanization and de-risking of these antibodies … Continue reading

ModiQuest Research expands its antibody portfolio – get 30% discount!

Place your order for antibody MQR2.1201, MQR2.1301, MQR2.1401, MQR2.1501 and/or MQR2.1601 get a 30% introduction discount on these products (only in November and December 2017)!* ModiQuest Research BV today announced that it has expanded its antibody portfolio with five different  monoclonal human antibodies. These antibodies are highly specific and developed for the detection of the following targets: … Continue reading

Citryll-ModiQuest will present at 2017 ACR/ARHP Annual Meeting, in San Diego, November 03-08, 2017

Citryll – ModiQuest will present at 2017 ACR/ARHP Annual Meeting, in San Diego, November 03-08, 2017 A poster will be presented entitled “Expanded Therapeutic ACPA Utility for Different NET-Driven Human (Autoimmune) Diseases”. Abstract is available online at: http://acrabstracts.org/abstract/expanded-therapeutic-acpa-utility-for-different-net-driven-human-autoimmune-diseases/ Details of the session see below: Session Name: Innate Immunity and Rheumatic Disease Poster I Date and Session … Continue reading

ModiQuest at the European Antibody Congress in Basel, October 31 – November 2, 2017

ModiQuest Research, a leading custom antibody generation and development company, will be attending the Protein engineering summit from October 31 till November 2 in Boston. Immunized animals are still a key source of antibodies generated within therapeutic campaigns to obtain high affinity antibody drug candidates. Therefore, humanization and de-risking of these antibodies is an important … Continue reading

ModiQuest Research will be attending the PEGS conference, Boston, 1-5 May 2017

ModiQuest Research, a leading custom antibody generation and development company, will be attending the Protein engineering summit this May 1-5 in Boston. Immunized animals are still a key source of antibodies generated within therapeutic campaigns to obtain high affinity antibody drug candidates. Therefore, humanization and de-risking of these antibodies is an important antibody engineering step … Continue reading

ModiQuest Research acquired ’Crédit d’Impôt Recherche’, CIR

We are pleased to announce that ModiQuest Research has acquired ’Crédit d’Impôt Recherche’ (CIR) accreditation from the French Ministry of Higher Education and Research. The French R&D tax credit initiative gives eligible research-based French companies, who are subject to corporate tax in France, the ability to claim significant tax reduction on costs generated in R&D … Continue reading

shopping basket 0 items

Shopping Cart

0

Your shopping cart is empty:

please visit the shop